Biotech 2050 Podcast

Rahul Chaturvedi

Booking Overview

This interview-led biotech industry show examines scientific, commercial, investment, and leadership disruptions shaping drug development, typically featuring senior biotech and pharmaceutical executives, investors, and scientific or technology leaders. Credible pitches include biotech founders and CEOs, drug-discovery and AI specialists, clinical-development leaders, healthcare investors, and patient-focused life-sciences executives; booking is likely high difficulty because recent guests hold prominent leadership positions and have substantial operating or scientific achievements.

Metrics

Episodes: 265

Frequency: Irregular

Rating: 4.7/5.0

Estimated listeners: 1,000 - 10,000

Listener location: USA

Contact Information

Publicly listed emails

jean@biotech2050.com

Looking for the right person? Join Podseeker to find direct host and producer contacts and manage your podcast outreach.

Host

Rahul Chaturvedi - Rahul Chaturvedi hosts Biotech 2050, exploring the scientific, strategic, financial, and leadership forces shaping the future of the biotechnology industry.

Booking Intelligence

Booking Requirements

high

Typical Credentials:

Senior biotech or pharmaceutical executives, company founders and CEOs, healthcare investors, drug-discovery scientists, AI and computational-biology leaders, and patient or clinical-development specialists with substantial operating, scientific, investment, or therapeutic-area expertise.

Required Achievements:

Founded or led biotech and pharmaceutical companies, Advanced clinical-stage or approved therapies, Built drug-discovery or technology platforms, Raised capital or led major healthcare investments, Held senior commercial, scientific, clinical, or patient-advocacy roles, Published significant scientific work or developed novel therapeutic approaches

Recent Guest Discussions

Nello Mainolfi - Targeted Protein Degradation, Drug Discovery, Biotech Company Building, Immunology, Clinical Development, Hiring, Culture, And Leadership.

Nick Myerberg - Artificial Intelligence In Drug Discovery, Computational Biology, Proprietary Data, Autonomous Laboratories, Ai-designed Medicines, Biotech Investing, And The Economics Of Drug Development.

Robert Jacks - Precision Medicine, Biotech Strategy, Leadership, Capital Allocation, Clinical Development, Cortisol Biology, Metabolic Disease, And Company Building.

Laura Williams - Patient-centric Drug Development, Patient Advocacy, Clinical-trial Diversity, Healthcare Leadership, And Embedding Patient Priorities In Biotech Operations.

Mike Raab - Patient-centric Biotech Leadership, Commercialization, Regulatory Adversity, Clinical-trial Diversity, Patient Advocacy, And Building Resilient Companies.

Recent Topics

Science, Biotechnology, Drug Discovery, Clinical Development, Biotech Leadership

Episodes

Here's the recent few episodes on

Biotech 2050 Podcast

Robert Plenge, EVP & Chief Research Officer, BMS: Reinventing Drug Discovery

September 24, 2026

Synopsis: The drug discovery industry faces a persistent challenge: 9 out of 10 drugs entering the clinic fail, underscoring the need for a better path from biological insight to transformative medicine. Host Rahul Chaturvedi speaks with Robert Plenge, Executive Vice President and Chief Research Officer at Bristol Myers Squibb, about how causal human biology, genetics, novel targets, and emerging technologies are reshaping drug discovery. Robert traces his unconventional journey from aspi...

Nello Mainolfi, Founder, President & CEO, Kymera: Pioneering Targeted Protein Degradation

September 16, 2026

Synopsis: What does it take to turn a once-fringe scientific idea into a new approach to drug discovery—and build a biotech company around it for the long haul? In this episode of Biotech 2050, host Rahul Chaturvedi sits down with Nello Mainolfi, Founder, President & CEO of Kymera Therapeutics, to explore his journey from chemist and drug hunter to biotech founder, and the decade-long evolution of Kymera into a leader in targeted protein degradation. Nello shares how scientific curiosity ...

Nick Myerberg, Partner & Head of AI at Braidwell on AI's Next Era in Drug Discovery

August 03, 2026

Synopsis: The guest on today's podcast is a representative of Braidwell LP, a registered investment adviser. Braidwell invests on behalf of its clients and either holds, or may in the future hold, positions in the securities discussed. His statements are not intended to provide investment advice, discuss comprehensive investment risks, or constitute an offer to transact in any security. The information presented is for general information purposes only and will not be updated. For years, A...

Publicly listed emails

jean@biotech2050.com

Looking for the right person? Join Podseeker to find direct host and producer contacts and manage your podcast outreach.

Get your clients booked on top podcasts

Try us risk free with a FREE 3 days trial.

Start Your Free Trial

Join hundreds of PR teams using Podseeker to pitch and land bookings